SOURCE: Washington G-2 Reports

Washington G-2 Reports

May 24, 2010 12:47 ET

Molecular Diagnostic Experts Identify Keys to Continued Growth

Washington G-2 Reports' Recent Conference Sets Groundwork for the Future of MDx

PETERBOROUGH, NH--(Marketwire - May 24, 2010) -  The 2010 Molecular Diagnostics conference surpassed all expectations as the event's faculty of thought leaders isolated the drivers and unique challenges of the fastest growing segment of the $55 billion clinical laboratory industry. During the three-day event, hundreds of professionals from across the spectrum of molecular diagnostics expertise listened in as the industry's future was detailed from a variety of perspectives.

Presented by Washington G-2 Reports (www.G2reports.com), the event identified the key trends that are likely to impact the business strategies of clinical labs that perform molecular diagnostic testing, both long and short term including:

  • A call from within the industry to expand awareness of and regulatory attention to diagnostics generally and molecular diagnostics in particular, from Mara Aspinall, President and CEO of next generation diagnostics firm On-Q-ity.
  • Projections of robust growth (approximately 12% CAGR) in molecular diagnostics as tests are increasingly commercialized, new clinical laboratories enter the field, and healthcare reform requires insurers to implement and reimburse for screening, prevention, and wellness measures as identified by Stephanie Murg, Editor, Washington G-2's Diagnostic Testing & Technology Report
  • The need to accelerate efforts to standardize and "curate" genomic data with the goal of making it more clinically relevant and actionable, as highlighted by George Church, founder of the Personal Genome Project, Professor of Genetics, Harvard Medical School, and Director, Center for Computational Genetics
  • The prediction that the legality of gene patents will ultimately be decided by the Supreme Court

Others constituting the 2010 Molecular Diagnostics conference faculty include Bassem A. Bejjani, Signature Genomics; Kenneth H. Buetow, NCI; John Greg Howe, Yale University; Victoria Joshi, Partners HealthCare Center for Personalized Genetic Medicine; Steven Keiles, Ambry Genetics and National Society of Genetic Counselors; Marina Kondratovich, U.S. Food & Drug Administration; Michael Kuo, University of California-San Diego Medical School; Mark Lovell, University of Colorado Denver and The Children's Hospital of Aurora, Colo.; Bryan Moore, Roche Diagnostics; Duane Newton, University of Michigan Hospitals and Health Centers; Beth Arnold, Foley Hoag; Diana Voorhees, Principal/CEO, DV & Associates Inc.; Rina Wolf, XIFIN; Alan H.B. Wu, San Francisco General Hospital & Trauma Center; Matt Zubiller, McKesson.

About Washington G-2 Reports and the Molecular Diagnostics Conference
Washington G-2 Reports offers timely, accurate market research and as well as reporting and analysis of legislative, regulatory, legal and business affairs directly affecting the operations and financial performance of our clients. Covering the industry for over 30 years, Washington G-2 Reports provides topical and analytical periodicals, proprietary research studies, custom advisory services, and in-person programming for providers of diagnostic testing and related medical services.

The annual Molecular Diagnostics conference is the preeminent gathering of molecular and genetics experts and business leaders representing the nation's top molecular laboratories. The event's focus areas are adjusted each year to provide timely answers to the most critical issues facing MDx. The 2010 event operated under the theme: Putting MDx to the Test: How Your Lab Can Capitalize on Molecular Diagnostics. Recordings of the 2010 event are available at http://www.g2reports.com/molecular10, or by calling 800-401-5937.

Contact Information

  • Contact:
    Dan Houder
    603-924-0900 x673